Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

July 23, 2019

ACADIA announces top-line results from phase 3 schizophrenia trial of Pimavanserin

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced top-line results from its Phase 3 ENHANCE study, which evaluated pimavanserin as an adjunctive treatment in adult schizophrenia patients with persistent inadequate response to their current antipsychotic therapy.

ACADIA announces top-line results from phase 3 schizophrenia trial of Pimavanserin